Having trouble accessing articles? Reset your cache.

AMG 386: Updated Phase II data

Updated data from a double-blind Phase II trial in 161 patients showed that 3 mg/kg IV AMG 386 plus paclitaxel significantly improved median PFS vs. placebo plus paclitaxel (7.4 vs. 5

Read the full 314 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE